Japanese pharma company Astellas Pharma has agreed to acquire Nasdaq-listed Iveric Bio in an all-cash deal worth around $5.9 billion with an aim to create a world-class ophthalmology player, while advancing the former’s primary focus on blindness and regeneration. Based in New Jersey, Iveric Bio is a biopharma company engaged in discovering and developing novel […]
Astellas Pharma has signed an agreement to acquire a 15% stake in US-based biotech company Taysha GeneTherapies through an investment of $50 million. As part of the transaction, the Japanese pharmaceutical company will get an exclusive option to license Taysha GeneTherapies’ TSHA-102 and TSHA-120, two clinical-stage, single-gene therapies for rare genetic diseases. TSHA-102 is a […]
Pandion Therapeutics has bagged a $795 million worth license and collaboration deal with Japanese pharma company Astellas Pharma for the research, development, and commercialization of locally acting immunomodulators targeting autoimmune diseases of the pancreas. The collaboration will bring together the modular biologics and functional immunology expertise of Cambridge-based biotech company and Astellas Pharma’s advanced therapeutics […]